TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01336257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SEBASTIAN Clinical Decision Support System (CDSS)
Description: SEBASTIAN is an example of a clinical decision support technology that supports the latest, service-based architectural approach to CDSS implementation. Developed at Duke University, SEBASTIAN is a clinical decision support Web service whose interface is now the basis of the HL7 Decision Support Service draft standard SEBASTIAN places a standardized interface in front of clinical decision support knowledge modules and makes only limited demands on how relevant patient data are collected or on how decision support inferences are communicated to end-users
Study: NCT04369586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meplazumab for injection
Description: single dose: 6 dose level, multiple dose: 0.3mg/kg/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meplazumab for injection
Description: single dose: 6 dose level, multiple dose: 0.3mg/kg/dose
Study: NCT03049579

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Weiquan Yogurt without probiotics
Description: 150 ml daily consumption for a total of 12 weeks
Study: NCT02850965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501
Study: NCT01248988

Intervention type: OTHER
Intervention: Synflorix™ Data collection
Description: Safety monitoring: recording of adverse events during using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
Study: NCT04369586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meplazumab for injection
Description: single dose: 6 dose level, multiple dose: 0.3mg/kg/dose
Study: NCT01101282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) mask therapy
Description: PEP mask therapy will be performed once/day, supervised, by an experienced physiotherapist until hospital discharge or ≥ 24 hours without sputum expectoration (whichever comes first). Written instructions shall also be provided, encouraging two more independent PEP mask sessions per day. Each session will comprise up to 5 cycles of 8-10 slightly active breaths, followed by 2 huffs (FET) and 2 coughs. A target pressure of 10-20 cms H20 during the middle of expiration shall be used (monitored via a pressure manometer).
Study: NCT04370587

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered up to 4mL as an intratumoral injection given Q2W.
Study: NCT02850965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira
Study: NCT04370587

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered up to 4mL as an intratumoral injection given Q2W.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered up to 4mL as an intratumoral injection given Q2W.
Study: NCT04370587

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: T3011 + pembrolizumab
Description: T3011 will be administered up to 4mL as an intratumoral injection in combination with intravenous pembrolizumab given Q3W.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: T3011 + pembrolizumab
Description: T3011 will be administered up to 4mL as an intratumoral injection in combination with intravenous pembrolizumab given Q3W.
Study: NCT00789152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine
Description: desloratadine 5 mg daily x 8 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine
Description: desloratadine 5 mg daily x 8 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levocetirizine
Description: levocetirizine 5 mg daily x 8 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levocetirizine
Description: levocetirizine 5 mg daily x 8 days
Study: NCT00000428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Amitriptyline 25 mg po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline plus Fluoxitine
Description: Amitriptyline 25 mg po plus Fluoxitine 20 mg po
Study: NCT02463084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Diet
Description: a 28-day course of 3 meals per day plus 2 snack that are either low in saturated fats, glycemic index and salt.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Diet
Description: a 28-day course of 3 meals per day plus 2 snack that are either high in saturated fats, glycemic index and salt.
Study: NCT00620867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 800 mg oral tablet three time daily with meals for 6 weeks
Study: NCT04369586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study: NCT00620867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: 200 mg oral capsule once daily with morning meal for 6 weeks
Study: NCT04369586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study: NCT00620867

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matched placebo orally for 6 weeks
Study: NCT00464620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: oral agent, continuous dosing, Cycles = 28 days
Study: NCT02383810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elsiglutide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elsiglutide
Study: NCT02868775

Intervention type: PROCEDURE
Intervention: cystoscopy, bladder hydrodistention and bladder biopsy
Study: NCT04194034

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG6002
Description: Phase I part: Dose escalation from 1 x 10E6 PFU to 1 x 10E9 PFU. Phase II part: Established recommended Phase II dose (RP2D).~Intrahepatic arterial (IHA) administration on Day 1 within a 14-day cycle of TG6002/5-FC combination treatment.~A second cycle of TG6002/5-FC combination starting with TG6002 (IHA) administration at the same dose on Day43 can be initiated if no progressive disease or Dose Limiting Toxicity event in between; maximum 2 cycles of TG6002/5-FC combination treatment for each patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flucytosine (5-FC)
Description: Oral administration 4 times per day at the total dose of 200 mg/kg/day for 10 consecutive days per 14-day cycle of TG6002/5-FC combination.~A second cycle of TG6002/5-FC combination will be initiated if no progressive disease or Dose Limiting Toxicity event in between.
Study: NCT00306215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX282-B
Description: CCX282-B or placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX282-B
Description: CCX282-B or placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX282-B
Description: CCX282-B or placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX282-B
Description: CCX282-B or placebo capsules
Study: NCT04235985

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Chlorhexidine Gluconate with HUBS
Description: 4% CHG soap will be applied to HUBS following manufacturers recommendation and applied to skin for different application times as dictated by the randomization of the marked sites on the forearm. Followed by a HUBS moistened with water.
Study: NCT02383810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elsiglutide
Study: NCT02852538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NEW FED TR
Description: NEW FED TR is a five day treatment for adults with anorexia nervosa. It is a neurobiologically informed, interactive, family-based treatment that draws upon the specific etiological traits characterizing anorexia nervosa. It stands for Neurobiological research findings Enhanced With Family/Friends of those with Eating Disorders, addressing Trait Responses that both create a vulnerability to the illness and serve as markers for recovery through treatment (formerly reported as Temperament-Based Treatment).
Study: NCT04489563

Intervention type: DEVICE
Group type: OTHER
Intervention: i-ACT
Description: Performing exercises with an adapted motion detection device (i.ACT) for 20-30 minutes.
Study: NCT03944915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given through IV infusions for 30-60 minutes on day 1 of each cycle. Each cycle will last 21 days. There will be 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: During Induction Therapy Paclitaxel (100 mg) will be given through IV infusions on days 1, 8 and 15 of each 21 day cycle. There will be 3 cycles.~During Radiotherapy, paclitaxel will be given after a dose of radiation by IV infusion for 60 minutes after day 1 of radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: During Induction Therapy Paclitaxel (100 mg) will be given through IV infusions on days 1, 8 and 15 of each 21 day cycle. There will be 3 cycles.~During Radiotherapy, paclitaxel will be given after a dose of radiation by IV infusion for 60 minutes after day 1 of radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given through IV infusions at 360 mg on day 1 every 21 days for 3 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Patients will receive 4.5-5 cycles of radiation depending on response. Those with a positive response will receive radiation for 4.5 cycles with a total radiation dose of 66 Gy. Patients with a moderate or no response will receive 5 cycles with a total radiation dose of 70-75 Gy. 2 times a day for days 1-5 followed by a rest period for days 6-13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea Pill
Description: One dose of hydroxyurea pill by mouth at start of 5-FU infusion during radiotherapy cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-FU will be given by IV infusion continuously for 5 days during radiotherapy cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim Injection
Description: Filgrastim shot will be given if patient has certain side effects during radiotherapy cycle on days 6-12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Radiotherapy may also be given with a different chemotherapy agent called cisplatin. This is the traditional standard of care chemotherapy regimen. In this case, the radiotherapy will be given once daily for 5 days per week. Cisplatin will be administered via IV once every 21 days for 2 or 3 cycles.
Study: NCT02423876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Description: Receive epidural placement. Standard epidural medications and dosage are as follows:~* 0.1% ropivicaine + 10 mcg/mL hydromorphone at 6 mL/hr continuous rate~* 3 mL/hr RN bolus, to be used as needed based on pain ratings~* 3 mL/30 minutes patient bolus, which is available on patient demand.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative Complication Management and Prevention
Description: Undergo ERP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative Complication Management and Prevention
Description: Undergo ERP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pain Therapy
Description: Undergo ERP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pain Therapy
Description: Undergo ERP
Study: NCT01294267

Intervention type: DEVICE
Group type: OTHER
Intervention: Circulatory Support System
Description: Femoral angiography will be performed, and if the anatomy is suitable, the femoral artery preclosure technique will be employed. The Impella 2.5 will be inserted through th femoral artery into the left ventricle. Anti-coagulation will be titrated to achieve a therapeutic ACT level. Organ perfusion and Hemodynamic data will be collected during simulated VTs and throughout the course of the case. The performance level of the device may be adjusted during the case to quantify hemodynamic effects
Study: NCT02742480

Intervention type: DRUG
Intervention: Dabigatran
Study: NCT01048476

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lutein
Description: Dietary Supplement: 20mg Lutein; daily supplementation one year

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein
Description: Dietary Supplement: 10mg Lutein; daily supplementation one year

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Dietary Supplement: placebo; daily supplementation one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lutein and zeaxanthin
Description: Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year
Study: NCT03322995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First-line Chemotherapy
Description: The first-line therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or best available standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second-line Chemotherapy
Description: Second line therapies will be multi-agent and contain gemcitabine. Molecular profiling data from the initial endoscopic ultrasound (EUS)/ fine needle aspirate (FNA) biopsy may be used at the discretion of the treating physician.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: 50.4 Gy in 28 fractions.
Study: NCT03778541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75mg/m2/d concurrent with radiotherapy, taken for at least 20 days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiotherapy
Description: the regular radiation dose prescription is 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: hypofractionated radiotherapy
Description: the regular radiation dose prescription is 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.
Study: NCT02020694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for vitamin D)
Study: NCT02996136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flu Symptoms
Description: Flu Symptoms

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flu Symptoms
Description: Flu Symptoms
Study: NCT04319549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine irrigant
Description: Ketorolac tromethamine, a potent NSAID available in both oral and injectable forms, is over 400 times more potent as a selective inhibitor of COX-1 over COX-2 than many other drugs. When ketorolac tromethamine was used as an intracanal medicament in teeth with irreversible pulpitis undergoing root canal treatment, it contributed to significant post operative pain relief.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sodium hypochlorite irrigant
Description: NaOCl is the gold standard and the most commonly used root canal irrigant. NaOCl is able to dissolve the organic tissues inside root canal due to its alkalinity (pH11), which causes amino acid degradation and hydrolysis through the production of chloramine molecules. In addition, it possesses highly antibacterial effect and its low cost makes it the most frequently used root canal irrigant. Dual rinse is considered an effective time saving root canal irrigant with a better antibacterial property in comparison to NaOCl alone. In addition to its effectiveness on smear layer removal and reduction in the debris accumulation during root canal instrumentation.
Study: NCT03789071

Intervention type: DIAGNOSTIC_TEST
Intervention: External ultrasound evaluation of the airway
Description: Patients scheduled to have surgery under general anesthesia in whom tracheal intubation is planned, will have a clinical and ultrasound assessment of the airway before surgery. Information regarding laryngoscopy in the operating room will be recorded.
Study: NCT01951170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 162 milligrams (mg) tocilizumab was administered subcutaneously once weekly for 24 weeks
Study: NCT00557492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin (bevacizumab)
Description: 10 mg/kg, days 1, 15, 29 and 43

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemzar (Gemcitabine)
Description: On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiotherapy
Description: 3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy
Study: NCT01884805

Intervention type: DEVICE
Group type: OTHER
Intervention: Monocular Adaptive Optics Visual Simulator (AOVIS-I)
Description: The procedure is guided by the custom made software and its graphical user interface. The interface has been designed to be user-friendly, being very similar to the software usually managed by the clinicians in their daily professional practice. The complete procedure in one patient takes less than 5 minutes and is completely non-invasive. The optical measurements only involve the use of low power infrared laser and the visual testing is as simple for the patients as watching television and making responses.
Study: NCT04541797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Intervention group: Patients will be prescribed empagliflozin 10mg once a day and optimised medical therapy for 6 months and standard follow-up like the control group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group: Patients will have placebo and optimised medical therapy and will continue to have protocol driven therapy and follow-up appointments (currently 1 appointment every 3 months).

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Stress Cardiac Magnetic Resonance
Description: Imaging: All patients will have stress CMR examinations at recruitment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stress Cardiac Magnetic Resonance
Description: Imaging: All patients will have stress CMR examinations at recruitment.
Study: NCT03890848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wechat application reminder intervention
Description: precautions and rehabilitation progress reminders and other news by optimized WeChat applet regularly

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine guidance during discharge
Description: rehabilitation exercise guidance during routine discharge
Study: NCT00872872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZT/3TC 2 weeks after delivery
Description: AZT/3TC 300/150mg will be given every 12 hours for 1 week after NVP discontinuation in arm 1 and for 2 weeks after NVP discontinuation in arm 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZT/3TC 2 weeks after delivery
Description: AZT/3TC 300/150mg will be given every 12 hours for 1 week after NVP discontinuation in arm 1 and for 2 weeks after NVP discontinuation in arm 2.
Study: NCT04048681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet soda
Description: 12 oz can of artificially sweetened cola beverage (Diet Coke planned to be used but similar to Diet Pepsi or other Diet Colas)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular soda
Description: 12oz can of regular cola beverage (Coke planned but similar to Pepsi or other regular cola sodas)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Carbonated Water
Description: 12oz can of carbonated water (sparking water, selzter water) unflavored
Study: NCT00545519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thymoglobulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thymoglobulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thymoglobulin
Study: NCT02941484

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early oral intake
Description: early oral intake is started within 24 hours after pancreaticoduodenectomies following to the ERAS guideline
Study: NCT02383810

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03448497

Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional
Study: NCT01308905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLT-PET
Description: PET scan will be conducted at diagnosis, at the end of the first cycle of treatment and prior to the surgical procedure (resection).
Study: NCT04479553

Intervention type: DRUG
Intervention: Qizhi Tongluo Capsules
Description: Qizhi Tongluo Capsule, a Chinese patent medicine composed of 26 Chinese herbs, has been approved by China Food and Drug Administration for treating recovery period of ischemic stroke (drug approval numbers: B20171001).
Study: NCT03718312

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: clamping with pre-conditioning (PCl)
Description: PCI procedure: clamping of the supracellular thoracic aorta for 5 minutes followed by a 5-minutes de-clamping period.~PCI procedure is repeated twice.
Study: NCT01725295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NST
Description: A form of physical therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrotherapy
Study: NCT02742480

Intervention type: DRUG
Intervention: Acenocoumarol
Study: NCT04031157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predictix Antidepressant
Description: Predictix Antidepressant guided treatment
Study: NCT04306302

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC10V
Description: Participants will receive a single IM injection of ExPEC10V.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC10V
Description: Participants will receive a single IM injection of ExPEC10V.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive single IM injection of matching placebo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive single IM injection of matching placebo.
Study: NCT00992914

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sympathetic nerve block with 1% lidocaine 1-2 ml
Description: Stellate Ganglion Injection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Superficial subcutaneous injection
Description: Superficial subcutaneous injection with saline